Tammy Dusevic, DO
Family Medicine · Sterling Hts, MINPI 1255308615
Payments from drug & device makers
Across 203 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$487
- Lilly USA, LLC$483
- AbbVie$462
- Boehringer Ingelheim$289
- AstraZeneca$206
- Sanofi-aventis U.S. LLC$152
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,07998%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $487 |
| Lilly USA, LLC | 32 | $483 |
| AbbVie(2 entities) | 34 | $462 |
| Boehringer Ingelheim | 16 | $289 |
| AstraZeneca | 15 | $206 |
| Sanofi-aventis U.S. LLC | 8 | $152 |
| Pfizer | 8 | $137 |
| Amgen | 9 | $136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $112 |
| Endo Pharmaceuticals Inc. | 6 | $103 |
| Exact Sciences | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $76 |
| Axsome Therapeutics, Inc. | 2 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| GSK | 3 | $47 |
| Genentech USA, Inc. | 2 | $38 |
| Merck | 3 | $37 |
| Novartis | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,137 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $82,402 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $67,255 |
| JardianceEmpagliflozin | 58 | $65,181 |
| MounjaroTirzepatide | 43 | $56,613 |
| TrulicityDulaglutide | 42 | $50,030 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $43,227 |
| XareltoRivaroxaban | 41 | $31,170 |
| FarxigaDapagliflozin Propanediol | 27 | $28,467 |
| RybelsusSemaglutide | 14 | $25,723 |
| JanuviaSitagliptin Phosphate | 17 | $25,189 |
| MyrbetriqMirabegron | 23 | $16,477 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $14,727 |
| EliquisApixaban | 15 | $14,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,988 |
| TradjentaLinagliptin | 15 | $12,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $487 | $108,12691 claims |
| Lilly USA, LLCMounjaro, Trulicity | $483 | $106,64385 claims |
| Boehringer IngelheimJardiance, Tradjenta | $289 | $77,57873 claims |
| AstraZenecaFarxiga, Lokelma | $206 | $37,80538 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $47 | $31,69946 claims |
| MerckJanuvia | $37 | $25,18917 claims |
| PfizerEliquis, Premarin | $137 | $19,86128 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $16,47723 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $76 | $8,35618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Sterling Hts
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.